News
MAZE
28.43
+5.22%
1.41
Maze Therapeutics CEO Jason V. Coloma sells USD 723,021 in common shares
PUBT · 3d ago
Mizuho Securities Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TipRanks · 4d ago
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
TipRanks · 5d ago
Weekly Report: what happened at MAZE last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at MAZE last week (0608-0612)?
Weekly Report · 06/15 09:24
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
TipRanks · 06/10 22:07
Weekly Report: what happened at MAZE last week (0601-0605)?
Weekly Report · 06/08 09:23
Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83
PUBT · 06/03 21:04
Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47
PUBT · 06/03 21:02
Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline
PUBT · 06/03 11:10
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554
PUBT · 06/02 20:12
Weekly Report: what happened at MAZE last week (0525-0529)?
Weekly Report · 06/01 09:24
Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45
PUBT · 05/27 20:17
Maze Therapeutics CEO to present at Jefferies Global Healthcare Conference
PUBT · 05/27 11:07
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Barchart · 05/27 06:03
Weekly Report: what happened at MAZE last week (0518-0522)?
Weekly Report · 05/25 09:25
J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
TipRanks · 05/23 12:15
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
TipRanks · 05/22 23:27
Maze Therapeutics SVP Finance Amy Bachrodt resigns, effective June 1
PUBT · 05/22 21:25
More
Webull provides a variety of real-time MAZE stock news. You can receive the latest news about Maze Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.